Transjugular Intrahepatic Portosystemic Shunt

TIPS Basics - Shuntastic Voyage

• Definition: A radiologically created shunt connecting the portal vein (PV) to a hepatic vein (HV) through the liver parenchyma.
• Access: Typically via the right internal jugular vein.
• Mechanism: A stent-graft is placed, creating a low-resistance pathway for portal blood to bypass the cirrhotic liver, directly entering systemic circulation.
• Goal: ↓ Portal pressure, alleviating complications of portal hypertension.
• Key Effect: Reduces portosystemic gradient (PSG).

⭐ Successful TIPS typically reduces the portosystemic gradient (PSG) to below 12 mmHg or by at least 50% from baseline to effectively manage variceal bleeding risk and refractory ascites.

The TIPS Procedure - Navigating the Liver

• Access Route: Right Internal Jugular Vein (Rt. IJV) preferred → Superior Vena Cava (SVC) → Right Atrium (RA) → Inferior Vena Cava (IVC) → Hepatic Vein (HV), typically Right HV.
• Guidance & Initial Steps: Fluoroscopy (primary); Ultrasound (IJV access). Wedged hepatic venography & portography (visualize Portal Vein).
• Parenchymal Puncture: From HV, advance needle (e.g., Colapinto) anteriorly/medially into intrahepatic Portal Vein (PV) branch. Confirm PV access.
• Shunt Creation & Stenting: Guidewire into PV (e.g., Superior Mesenteric Vein/Splenic Vein). Dilate tract (8-10 mm balloon). Deploy covered stent-graft (PTFE) from PV to HV.
• Hemodynamic Goal: Target Portosystemic Gradient (PSG) < 12 mmHg or ≥50% reduction from baseline.

⭐ Covered stents (e.g., Viatorr) significantly improve primary patency by reducing bile duct injury and intimal hyperplasia compared to bare metal stents.

TIPS Hurdles - Shunt Shenanigans

Contraindications (CI): ⚠️

• Absolute:
  • CHF, severe pulm HTN (mPAP > 45 mmHg)
  • Severe tricuspid regurgitation
  • Polycystic liver disease (extensive)
  • Uncontrolled sepsis/infection
  • Unrelieved biliary obstruction
• Relative:
  • Active HCC
  • Severe coagulopathy (INR > 5, Plt < 20k), uncorrectable
  • Central tumors obstructing IVC/hepatic veins

Complications:

• Early (< 30 days):
  • HE (most common, ~30-50%)
  • Hemorrhage (capsular/intraperitoneal), neck hematoma
  • Stent issues: malposition, migration, infection, thrombosis
  • Acute liver failure, hemolysis
• Late (> 30 days):
  • Shunt stenosis/occlusion (common late)
  • Worsening/refractory HE
  • Progressive liver failure

Shunt Dysfunction:

• Causes:
  • Neointimal hyperplasia (commonest for stenosis)
  • Thrombosis (acute/chronic)
  • Stent migration or kinking
• Sx: Recurrent ascites, variceal bleed
• Dx: Doppler US (flow changes), portography

⭐ > New or worsening hepatic encephalopathy: most common post-TIPS complication, affects up to 50%.

TIPS Check-up - Shunt Surveillance

• Goal: Maintain shunt patency & prevent complications (e.g., hepatic encephalopathy, shunt stenosis/occlusion).
• Initial Check: Doppler Ultrasound (DUS) within 24-72 hours post-TIPS.
• Routine Surveillance (DUS):
  • At 1, 3, 6 months post-procedure.
  • Then every 6-12 months lifelong.
• Key Parameters Assessed:
  • Shunt patency and morphology.
  • Peak Shunt Velocity (PSV): Normal range 90-190 cm/s.
• Signs of Dysfunction on DUS:
  • PSV < 90 cm/s or > 190 cm/s.
  • Significant PSV change from baseline (e.g., ↑ > 50% or ↓ > 40%).
  • Focal velocity ↑ (stenosis); no flow (occlusion).
  • Clinical: Recurrence of ascites or variceal bleeding.

⭐ Doppler ultrasound is the primary non-invasive modality for routine TIPS surveillance, assessing flow velocities and identifying stenosis or occlusion.

• Management of Dysfunction: Confirm with portography/venography & pressure measurements; consider angioplasty, re-stenting, or parallel TIPS if indicated.

High‑Yield Points - ⚡ Biggest Takeaways

• TIPS: Shunt between hepatic vein (e.g., RHV) and portal vein (e.g., RPV) via stent.
• Primary indications: Refractory variceal hemorrhage and refractory ascites.
• Most common significant complication: New or worsening hepatic encephalopathy.
• Key contraindications: Severe heart failure (NYHA III/IV), severe pulmonary hypertension, uncontrolled systemic infection.
• Doppler ultrasound is primary for monitoring shunt patency.
• Therapeutic goal: ↓ Portosystemic gradient (PSG) to <12 mmHg or by >50%.
• Covered stents preferred over bare stents for ↑ long-term patency.